2KUG

Halothane binds to druggable sites in calcium-calmodulin: Solution Structure of halothane-CaM N-terminal domain

SOLUTION NMR

NMR Experiment
Experiment	Type	Sample Contents	Solvent	Ionic Strength	pH	Pressure	Temperature (K)	Spectrometer
1	3D HNCO	2 mM [U-99% 13C; U-99% 15N] CALMODULIN, 20 mM CALCIUM ION, 20 mM N-{[2-({[1-(4-CARBOXYBUTANOYL)AMINO]-2-PHENYLETHYL}-HYDROXYPHOSPHINYL)OXY]ACETYL}-2-PHENYLETHYLAMINE	95% H2O/5% D2O	0.1	7.2	ambient	298
2	3D HNCA	2 mM [U-99% 13C; U-99% 15N] CALMODULIN, 20 mM CALCIUM ION, 20 mM N-{[2-({[1-(4-CARBOXYBUTANOYL)AMINO]-2-PHENYLETHYL}-HYDROXYPHOSPHINYL)OXY]ACETYL}-2-PHENYLETHYLAMINE	95% H2O/5% D2O	0.1	7.2	ambient	298
3	3D HNCACB	2 mM [U-99% 13C; U-99% 15N] CALMODULIN, 20 mM CALCIUM ION, 20 mM N-{[2-({[1-(4-CARBOXYBUTANOYL)AMINO]-2-PHENYLETHYL}-HYDROXYPHOSPHINYL)OXY]ACETYL}-2-PHENYLETHYLAMINE	95% H2O/5% D2O	0.1	7.2	ambient	298
4	3D HBHA(CO)NH	2 mM [U-99% 13C; U-99% 15N] CALMODULIN, 20 mM CALCIUM ION, 20 mM N-{[2-({[1-(4-CARBOXYBUTANOYL)AMINO]-2-PHENYLETHYL}-HYDROXYPHOSPHINYL)OXY]ACETYL}-2-PHENYLETHYLAMINE	95% H2O/5% D2O	0.1	7.2	ambient	298
5	3D H(CCO)NH	2 mM [U-99% 13C; U-99% 15N] CALMODULIN, 20 mM CALCIUM ION, 20 mM N-{[2-({[1-(4-CARBOXYBUTANOYL)AMINO]-2-PHENYLETHYL}-HYDROXYPHOSPHINYL)OXY]ACETYL}-2-PHENYLETHYLAMINE	95% H2O/5% D2O	0.1	7.2	ambient	298
6	3D HCCH-TOCSY	2 mM [U-99% 13C; U-99% 15N] CALMODULIN, 20 mM CALCIUM ION, 20 mM N-{[2-({[1-(4-CARBOXYBUTANOYL)AMINO]-2-PHENYLETHYL}-HYDROXYPHOSPHINYL)OXY]ACETYL}-2-PHENYLETHYLAMINE	95% H2O/5% D2O	0.1	7.2	ambient	298
7	3D 1H-15N NOESY	2 mM [U-99% 13C; U-99% 15N] CALMODULIN, 20 mM CALCIUM ION, 20 mM N-{[2-({[1-(4-CARBOXYBUTANOYL)AMINO]-2-PHENYLETHYL}-HYDROXYPHOSPHINYL)OXY]ACETYL}-2-PHENYLETHYLAMINE	95% H2O/5% D2O	0.1	7.2	ambient	298
8	3D 1H-13C NOESY	2 mM [U-99% 13C; U-99% 15N] CALMODULIN, 20 mM CALCIUM ION, 20 mM N-{[2-({[1-(4-CARBOXYBUTANOYL)AMINO]-2-PHENYLETHYL}-HYDROXYPHOSPHINYL)OXY]ACETYL}-2-PHENYLETHYLAMINE	95% H2O/5% D2O	0.1	7.2	ambient	298
9	3D HNHA	2 mM [U-99% 15N] CALMODULIN, 20 mM CALCIUM ION, 20 mM N-{[2-({[1-(4-CARBOXYBUTANOYL)AMINO]-2-PHENYLETHYL}-HYDROXYPHOSPHINYL)OXY]ACETYL}-2-PHENYLETHYLAMINE	95% H2O/5% D2O	0.1	7.2	ambient	298
10	3D HCCH-COSY	2 mM [U-99% 13C; U-99% 15N] CALMODULIN, 20 mM CALCIUM ION, 20 mM N-{[2-({[1-(4-CARBOXYBUTANOYL)AMINO]-2-PHENYLETHYL}-HYDROXYPHOSPHINYL)OXY]ACETYL}-2-PHENYLETHYLAMINE	95% H2O/5% D2O	0.1	7.2	ambient	298
11	3D 1H-15N NOE	2 mM [U-99% 15N] CALMODULIN, 20 mM CALCIUM ION, 20 mM N-{[2-({[1-(4-CARBOXYBUTANOYL)AMINO]-2-PHENYLETHYL}-HYDROXYPHOSPHINYL)OXY]ACETYL}-2-PHENYLETHYLAMINE	95% H2O/5% D2O	0.1	7.2	ambient	298

NMR Spectrometer Information
Spectrometer	Manufacturer	Model	Field Strength
1	Bruker	AVANCE	700
2	Bruker	AVANCE	500

NMR Refinement
Method	Details	Software
simulated annealing, CHARMm22 energy minimization	100 step steepest descent - final refinement	X-PLOR

NMR Ensemble Information
Conformer Selection Criteria	structures with the lowest energy
Conformers Calculated Total Number	50
Conformers Submitted Total Number	5
Representative Model	1 (closest to the average)

Computation: NMR Software
#	Classification	Version	Software Name	Author
1	geometry optimization	X-PLOR	MSI XPLOR 3.843	Brunger
2	refinement	X-PLOR	MSI XPLOR 3.843	Brunger

RCSB PDB Core Operations are funded by the National Science Foundation (DBI-1832184), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.